AIM: To evaluate ovarian function after modern intensive multi-agent chemotherapy for @entity421 given during childhood or adolescence. METHODS: After discontinuation of treatment, 10 female @entity421 survivors were followed up for 1.5-14 (median 4.6) years. Their age at diagnosis was a median of 12.9 (range 6-15) years and at the last follow up 18.6 (range 16-22). The main follow up included recording of their pubertal and menstrual status and of sex hormone determinations. RESULTS: Prior to diagnosis, 5/10 had had their menarche, and one had it while on therapy. At discontinuation of chemotherapy, ovarian function had severely deteriorated; none of the @entity1 experienced regular menstrual cycles. However, during follow up, significant @entity2670 was evident. At the last follow up, 9/10 @entity1 were menstruating spontaneously. During follow up, four @entity1 , three of whom had received high doses of alkylating agents, presented with clear hypergonadotrophism with high FSH levels (14.4-132 IU/l). Three of these four @entity1 initiated menstruation after their gonadotrophin levels normalised. CONCLUSIONS: The modern multi-agent chemotherapy applied for @entity2670 . @entity2670 is common, even in cases with severe @entity2746 , but may only occur after several years off chemotherapy. Regular assessment of ovarian function and cautious use of hormone replacement therapy are important in @entity1 with chemotherapy induced @entity10844 .

Restoration of ovarian function after chemotherapy for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'girls'] @entity10844 :: ('MESH:D006058', 'Disease') :: ['gonadal damage'] @entity421 :: ('MESH:D012516', 'Disease') :: ['osteosarcoma'] @entity2670 :: ('MESH:D010049', 'Disease') :: ['osteosarcoma impairs ovarian function', 'Normalisation of ovarian function', 'restoration of ovarian function'] @entity2746 :: ('MESH:D013132', 'Disease') :: ['hypergonadotrophic hypogonadism']
@entity421 :: (MESH:D012516,Disease) :: ['osteosarcoma']
